Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025

Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin

Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer

Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer

Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.

Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.

Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをもとに、その活用法についてディスカッションしました。

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.